Workflow
直通部委｜外交部：中国对俄罗斯试行免签 国资委：打造生物医药领域国家队
Xin Lang Cai Jing·2025-09-02 10:12

Group 1: International Relations and Trade - China will implement a visa-free policy for Russian citizens holding ordinary passports from September 15, 2025, to September 14, 2026, allowing stays of up to 30 days for business, tourism, family visits, and transit [1] - The Shanghai Cooperation Organization (SCO) leaders have issued a statement supporting the multilateral trading system, emphasizing the importance of development and the integration of least developed countries into the trade system [1] - China aims to strengthen communication and cooperation with SCO member states to promote genuine multilateralism and push for reforms in the World Trade Organization (WTO) [1] Group 2: Social Security and Tax Policies - The Ministry of Finance and the State Taxation Administration have announced tax policies regarding the transfer of state-owned equity and cash income to bolster the social security fund, including exemptions from VAT and corporate income tax for certain transactions [2] - The policy aims to facilitate the management of state-owned assets and enhance the financial sustainability of the social security fund [2] Group 3: Software Industry Performance - In the first seven months of 2025, China's software industry generated revenue of 83,246 billion yuan, reflecting a year-on-year growth of 12.3% [3] - The total profit of the software industry reached 10,890 billion yuan, with software product revenue accounting for 21.6% of the total industry revenue [3] - Information technology services contributed 57,246 billion yuan, representing 68.8% of the overall revenue, indicating a strong performance in this sector [3] Group 4: Biopharmaceutical Industry Development - The State-owned Assets Supervision and Administration Commission (SASAC) is focusing on accelerating the development of the biopharmaceutical industry, aiming to create a national team in this field [4] - The initiative emphasizes innovation-driven development and collaboration with the Chinese Academy of Sciences to enhance the quality and competitiveness of China's biopharmaceutical sector [4]